Companies · Biotechnology

Bio-Tree Systems, Inc.

Framingham · Biotechnology

Diligence memoA one-page analyst read on Bio-Tree Systems, Inc. — recommendation, valuation, rhythm, risks.→
$950K
Total raised · real
1
Rounds
—
Latest step-up
Top 84%
Sector rank · raised
Pre-Seed
Latest stage · inferred · Thu Jun 04 2009 00:00:00 GMT+0000 (Coordinated Universal Time)

Bio-Tree Systems, Inc. looks over-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Over-valued
  • Modeled value is 1.90× the median modeled value of Pre-Seed Biotechnology companies in 2007–2009 (62 peers) — value vs value, same stage and era.
Dormant
  • Last raise 17.1 yr ago; this sector typically re-raises about every 14 months.
  • Only one round on record and long silent — often defunct, acquired, or gone quiet.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Bio-Tree Systems, Inc. is one of 4293 Biotechnology companies tracked from Framingham. By capital raised it ranks in the long tail (ahead of 17% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$25M$50M$75M$100MPre-Seed · 2009-06-04 Raised $950K (real) Modeled valuation $52M (est)$950K$52MPre-Seed2009

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$950K · 2009

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$52.4M
Base estimate est.
$507K
Conservative case
$594.7M
Upside case
$5.3M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Pre-Seed — a round under $1.0M). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Not enough modeled valuation points to chart a trajectory.

Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
24%
Survival probability
10% low · 44% high
1.86×/yr
Annual markup
2.52×/yr upside case
6.0 yr
Elapsed time used
17.1 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
—
Avg between rounds
—
Capital velocity
17.3 yr
On record since
2009
First round
1
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages)▼ 0.1× of median
This company$950K
Sector median$7.2M
Latest round — vs other Pre-Seed rounds in sector (real $, this stage)▲ 2.3× above median
This company$950K
Sector median$412K
Modeled value — vs sector median (estimate, all stages)▼ 0.8× of median
This company$52.4M
Sector median$64.2M

Raised more than 17% of sector peers (real $). Modeled value above 46% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Pre-Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #4 of 62.

This companyCohort peer
$10.0M$100.0M$100K$1.0M$10.0MCapital raised (log)Cellay, Inc. · Pre-Seed Raised $1.0M · modeled $55.2M (est)Cellutions Inc · Pre-Seed Raised $1.0M · modeled $55.2M (est)Atherotech, Inc. · Pre-Seed Raised $999K · modeled $55.2M (est)Theocorp Holding Company, LLC · Pre-Seed Raised $900K · modeled $49.7M (est)Invoy Technologies, L.L.C. · Pre-Seed Raised $898K · modeled $49.6M (est)Amnis Corp · Pre-Seed Raised $894K · modeled $49.3M (est)Visen Medical Inc · Pre-Seed Raised $885K · modeled $48.9M (est)Orthera, Inc. · Pre-Seed Raised $1.6M · modeled $47.8M (est)Kika Medical International Co · Pre-Seed Raised $1.3M · modeled $46.9M (est)Octamer Inc · Pre-Seed Raised $821K · modeled $45.3M (est)Dynatherm Medical Inc · Pre-Seed Raised $818K · modeled $45.2M (est)Bio-Tree Systems, Inc. (this company) Raised $950K · modeled $52.4M (est)Bio-Tree Systems, Inc.
CompanyStageRaised · realValue · estvs peer med.
Cellay, Inc.Pre-Seed$1.0M$55.2M2.00×
Cellutions IncPre-Seed$1.0M$55.2M2.00×
Atherotech, Inc.Pre-Seed$999K$55.2M2.00×
Bio-Tree Systems, Inc. this companyPre-Seed$950K$52.4M1.90×
Theocorp Holding Company, LLCPre-Seed$900K$49.7M1.80×
Invoy Technologies, L.L.C.Pre-Seed$898K$49.6M1.80×
Amnis CorpPre-Seed$894K$49.3M1.79×
Visen Medical IncPre-Seed$885K$48.9M1.77×
Orthera, Inc.Pre-Seed$1.6M$47.8M1.73×
Kika Medical International CoPre-Seed$1.3M$46.9M1.70×
Octamer IncPre-Seed$821K$45.3M1.64×
Dynatherm Medical IncPre-Seed$818K$45.2M1.64×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$950K2009-06-04$5.3M$52.4M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$950K2009-06-04
    • First recorded raise — entered as Pre-Seed.
Intelligence
—
Modeled next raise
$1.5M
Modeled next size est.range $988K–$2.4M
—
Last step-up
—
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Bernard Gordon—3 other2009-06
Edwin L. Miller—1 other2009-06
Ethan Rasiel—1 other2009-06
Kenneth I. Kaitin—1 other2009-06
Joseph Mundy——2009-06
Raul A. Brauner——2009-06
Registry & provenance

Bio-Tree Systems, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1288765
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Curis IncBiotechnologyPre-Seed$964K$53.2Mnetwork1 shared operator · same sector · same stage
NanoTomer, Inc.BiotechnologyPre-Seed$950K$52.4Msame sector · same stage
ALRGN Bio, Inc.BiotechnologyPre-Seed$946K$52.2Msame sector · same stage
EternoGen Aesthetics, LLCBiotechnologyPre-Seed$939K$46.3Msame sector · same stage
Cyto Wave Technologies Inc.BiotechnologyPre-Seed$965K$53.3Msame sector · same stage
LightStat, LLCBiotechnologyPre-Seed$970K$53.6Msame sector · same stage
Real Imaging, Ltd.BiotechnologyPre-Seed$930K$51.3Msame sector · same stage
One World Lab, Inc.BiotechnologyPre-Seed$981K$54.2Msame sector · same stage
Frequently asked
How much funding has Bio-Tree Systems, Inc. raised?
Bio-Tree Systems, Inc. has raised approximately $950K in disclosed capital across 1 recorded financing round, aggregated from public filings.
What is Bio-Tree Systems, Inc.'s estimated valuation?
Provath's modeled valuation for Bio-Tree Systems, Inc. is approximately $52.4M (modeled range $507K–$594.7M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Bio-Tree Systems, Inc. at?
Bio-Tree Systems, Inc.'s latest modeled financing stage is Pre-Seed. Its most recent recorded round closed around Thu Jun 04.
What does Bio-Tree Systems, Inc. do and where is it based?
Bio-Tree Systems, Inc. operates in the Biotechnology sector, based in Framingham.
Explore related

See where Bio-Tree Systems, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Bio-Tree Systems, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.